Case Report: COVID-19 Vaccination Associated Fulminant Myocarditis

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Dao Wen Wang¹  Chunxia Zhao¹  Guanglin Cui¹  Rui Li¹ 

[1] Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Hubei Province Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China;

关键词: myocarditis;    COVID-19 vaccine;    immunomodulatory therapy;    myocyte necrosis;    pathogenesis;   

DOI  :  10.3389/fcvm.2021.769616

 received in 2021-09-02, accepted in 2021-12-31,  发布年份 2022

来源: Frontiers

【 摘 要 】

Herein, we describe a novel finding of fulminant myocarditis (FM) in two subjects the day after administration of the first dose of the currently available inactivated SARS-CoV-2 vaccine (Vero cell). Cardiac magnetic resonance imaging revealed extensive myocardial edema and necrosis. A pathologic evaluation of the endocardial biopsy tissues revealed inflammatory cell (lymphocytes) infiltration and interstitial edema, myocyte necrosis, and focal areas of fibrosis. A life-support-based comprehensive treatment regimen comprising mechanical circulatory support using intra-aortic balloon pulsation and immunomodulatory therapy—glucocorticoids and intravenous immunoglobulin—was used to treat the patients with FM; eventually, the patients recovered and were discharged. To our knowledge, these are the first two reported cases of FM, with no other identified cause or associated illness, after receiving the inactivated SARS-CoV-2 vaccine (Vero cell). These findings suggest a novel pathogenesis of myocarditis which mentions to pay more attention to this rare, but lethal complication of COVID-19 vaccination.

【 授权许可】

Unknown   
Copyright © 2022 Cui, Li, Zhao and Wang.